• Reference Citation Analysis
  • v
  • v
  • Find an Article
Today's Articles (11)   Subscriber (49313)
Number Citation Analysis
1
S304: SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2 YEAR FOLLOW-UP FROM THE CARDINAL STUDY. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000844108.70297.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]  Open
2
Lenalidomide following rituximab and fludarabine in untreated CLL. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6558] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
3
Cancer and women. Med Clin North Am 1998;82:321-33. [PMID: 9531928 DOI: 10.1016/s0025-7125(05)70609-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA